nach oben

Drugs

Erschienen in:

01.04.2008 | Adis Drug Profile

Dalbavancin

verfasst von: Vanessa R. Anderson, Gillian M. Keating

Erschienen in: Drugs | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

▴ Dalbavancin is a semisynthetic glycopeptide antibacterial agent that is active against Gram-positive bacteria associated with complicated skin and skin structure infections (cSSSIs). It is administered as a two-dose regimen intravenously infused over 0 minutes once weekly.
▴ The efficacy of dalbavancin (1000 mg on day 1 and 00 mg on day 8) has been examined in two randomized controlled trials in adults with cSSSIs. In each study, the primary efficacy measure was clinical success at the test-of-cure or follow-up visit in clinically evaluable patients.
▴ In a randomized, controlled, double-blind, multinational, phase III trial, dalbavancin was noninferior to linezolid, with clinical success rates of 88.9% and 1.2%.
▴ In a randomized, open-label, multicentre, phase II trial, clinical success rates were 94% with dalbavancin and 76% with comparator antibacterials.
▴ Dalbavancin was generally well tolerated by adult patients with cSSSIs, with most adverse events being of mild or moderate severity.

Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003; 63(14): 1459–80PubMedCrossRef

Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections [published erratum appears in Clin Infect Dis 2005 Dec 15; 41: 1830]. Clin Infect Dis 2005 Nov 15; 41(10): 1373–406PubMedCrossRef

Gemmell CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006 Apr; 57(4): 589–608PubMedCrossRef

Van Bambeke F, Van Laethem Y, Courvalin P, et al. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 2004; 64(9): 913–36PubMedCrossRef

Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin Microbiol Infect 2005 Feb; 11(2): 95–100PubMedCrossRef

Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 2005 Nov; 45(11): 1279–87PubMedCrossRef

Data on file. Pfizer. 2007 Jun 19

Biedenbach DJ, Ross JE, Fritsche TR, et al. Activity of dalbavancin tested against Staphylococcus spp. and β-haemolytic Streptococcus spp. isolated from fifty-two geographically diverse medical centers in the United States. J Clin Microbiol 2007 Mar; 45(3): 998–1004

Streit JM, Fritsche TR, Sader HS, et al. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004 Feb; 48(2): 137–43PubMedCrossRef

10.

Streit JM, Sader HS, Fritsche TR, et al. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis 2005 Dec; 53(4): 307–10PubMedCrossRef

11.

Jones RN, Fritsche TR, Sader HS, et al. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother 2005 Dec; 17(6): 593–600PubMed

12.

Bozdogan B, Ednie L, Credito K, et al. Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob Agents Chemother 2004 Dec; 48(12): 4762–5PubMedCrossRef

13.

Jones RN, Stilwell MG, Sader HS, et al. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis 2006 Feb; 54(2): 149–53PubMedCrossRef

14.

Goldstein EJ, Citron DM, Warren YA, et al. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 2006 Aug; 50(8): 2875–9PubMedCrossRef

15.

Lin G, Credito K, Ednie LM, et al. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005 Feb; 49(2): 770–2PubMedCrossRef

16.

Lopez S, Hackbarth C, Romano G, et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother 2005 Mar; 55 (Suppl. S2): ii21–4PubMedCrossRef

17.

Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005 Mar; 55 Suppl. 2: ii25–30PubMedCrossRef

18.

Goldstein BP, Jones RN, Fritsche TR, et al. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagn Microbiol Infect Dis 2006 Feb; 54(2): 83–7PubMedCrossRef

19.

Lefort A, Pavie J, Garry L, et al. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob Agents Chemother 2004 Mar; 48(3): 1061–4PubMedCrossRef

20.

Jabes D, Candiani G, Romano G, et al. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother 2004 Apr; 48(4): 1118–23PubMedCrossRef

21.

Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004 Mar; 48(3): 940–5PubMedCrossRef

22.

Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003 Nov 15; 37(10): 1298–303PubMedCrossRef

23.

Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007 May; 51(5): 1633–42PubMedCrossRef

24.

Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicrob Chemother 2006 Oct; 58(4): 802–5PubMedCrossRef

25.

Goldstein BP, Seltzer E, Flamm RK, et al. Dalbavancin (DAL) phase 3 skin and skin structure (SSSI) studies: pathogens and microbiological efficacy [abstract no. L-1577]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16–19; Washington, DC

26.

Dowell JA, Gottlieb AB, Van Saders C, et al. The pharmacokinetics and renal excretion of dalbavancin in healthy subjects [abstract no. A-1386 plus poster]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27–30; San Diego (CA), 18

27.

Nicolau DP, Sun HK, Seltzer E, et al. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 2007 Sep; 60(3): 681–4PubMedCrossRef

28.

Dowell JA, Seltzer E, Buckwalter M, et al. The pharmacokinetics of dalbavancin (DAL) in subjects with mild, moderate or severe hepatic impairment (HI) [abstract no. A-19 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC, 4

29.

Dowell J, Seltzer E, Stogniew M, et al. Dalbavancin dosage adjustments not required for patients with mild renal impairment [abstract no P1224]. Clin Microbiol Infect 2003; 9 Suppl. 1: 291

30.

Dowell J, Seltzer E, Stogniew MB, et al. Dalbavancin (DAL) pharmacokinetics (PK) in subjects with mild or moderate hepatic impairment (HI) [abstract no. A-19 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago (IL), 4

31.

Dowell JA, Buckwalter M, Seltzer E, et al. Dalbavancin penetration into skin supports once weekly dosing [abstract no. P895]. Clin Microbiol Infect 2005 Apr; 11 (Suppl. 2): 272

32.

Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 2005 Mar; 55 Suppl. 2: ii31–5PubMedCrossRef

33.

Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother 2006 Sep; 58(3): 627–31PubMedCrossRef

34.

Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005 Nov 15; 41(10): 1407–15PubMedCrossRef

35.

Carmeli Y, Rothermel C, Sheehan D, et al. Analysis of patients with community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) in a phase 3 study of dalbavancin (DAL) versus linezolid (LNZ) for the treatment of complicated skin and soft tissue infections (cSSTI) [abstract no. L-1211 plus poster]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA), 374

Titel: Dalbavancin
verfasst von: Vanessa R. Anderson
Gillian M. Keating
Publikationsdatum: 01.04.2008
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 5/2008
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200868050-00006

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Dalbavancin

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2008

Effect of Drugs on Defibrillation Capacity

Enoxaparin

Efficacy and Safety of Once-Daily Regimens in the Treatment of HIV Infection

Dalbavancin

β-Blockers and Coronary Flow Reserve

Lanreotide Autogel®